Throughout the last three months, 15 analysts have evaluated Doximity DOCS, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 4 | 10 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 2 | 0 | 0 |
| 2M Ago | 0 | 3 | 5 | 1 | 0 |
| 3M Ago | 0 | 1 | 2 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $53.6, with a high estimate of $75.00 and a low estimate of $33.00. Marking an increase of 58.07%, the current average surpasses the previous average price target of $33.91.
Diving into Analyst Ratings: An In-Depth Exploration
The standing of Doximity among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jeff Garro | Stephens & Co. | Announces | Equal-Weight | $55.00 | - |
| Steven Valiquette | Mizuho | Announces | Neutral | $55.00 | - |
| Anne Samuel | JP Morgan | Raises | Neutral | $48.00 | $30.00 |
| David Roman | Goldman Sachs | Announces | Neutral | $58.00 | - |
| Jailendra Singh | Truist Securities | Raises | Hold | $49.00 | $35.00 |
| Ricky Goldwasser | Morgan Stanley | Raises | Equal-Weight | $53.00 | $33.00 |
| Richard Close | Canaccord Genuity | Raises | Hold | $60.00 | $40.00 |
| Stephanie Davis | Barclays | Raises | Overweight | $75.00 | $52.00 |
| Brian Peterson | Raymond James | Raises | Outperform | $65.00 | $37.00 |
| Stan Berenshteyn | Wells Fargo | Raises | Equal-Weight | $41.00 | $19.00 |
| Scott Schoenhaus | Keybanc | Announces | Overweight | $70.00 | - |
| Ricky Goldwasser | Morgan Stanley | Raises | Underweight | $33.00 | $26.00 |
| Stephanie Davis | Barclays | Raises | Overweight | $52.00 | $35.00 |
| Elizabeth Anderson | Evercore ISI Group | Raises | In-Line | $45.00 | $34.00 |
| Allen Lutz | B of A Securities | Raises | Neutral | $45.00 | $32.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Doximity. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Doximity compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Doximity's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Capture valuable insights into Doximity's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Doximity analyst ratings.
All You Need to Know About Doximity
Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.
Financial Insights: Doximity
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Doximity's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 20.44%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Doximity's net margin is impressive, surpassing industry averages. With a net margin of 32.27%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Doximity's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.71% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Doximity's ROA stands out, surpassing industry averages. With an impressive ROA of 4.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
